Revah joins Genethon as ceo

Genethon, a biotherapy research centre created by the French Muscular Dystrophy Association (AFM), has appointed Frederic Revah as chief executive.

Genethon, a biotherapy research centre created by the French Muscular Dystrophy Association (AFM), has appointed Frederic Revah as chief executive.

Revah brings more than 20 years' experience in the pharmaceutical and biotech industries and academic research to the job.

Immediately prior to joining Genethon, Revah had been chief executive of the oncology start-up Sepal Pharma since 2008. Before that, he was vice president, Drug Discovery, and chief scientific officer of Cerep from 1999 to 2007 and chief executive of its oncology subsidiary.




You may also like

Research & Development

Gene therapy centre to open in France next year

Genethon BioProd to produce 20 clinical batches of gene therapy products a year
Regulatory

BetaGlue Therapeutics gains MHRA approval for pancreatic cancer trial

YntraDose, the innovative radiotherapy treatment for unresectable locally advanced pancreatic cancer, has been granted an early feasibility clinical investigation and will assess safety and performance in patients
Research & Development

Scottish immunology CRO RoukenBio celebrates 10 years of growth

Formerly known as Antibody Analytics, the contract research organisation has grown from three employees to over 100 and enjoyed successes such as the launch of its first proprietary technology, IndEx-2 and multi-million pound investments
Manufacturing

Abzena advances ADC development with ThioBridge conjugation technology

Next-generation conjugation delivers greater stability, potency and control for targeted cancer therapeutics
Research & Development

DBV Technologies announces last patient visit completed in Phase III peanut allergy trial in children

The Phase III VITESSE clinical trial of the VIASKIN Peanut patch in peanut allergic children aged 4-7 years remains on track for topline data in Q4 of this year
Research & Development

Medicines Discovery Catapult announces collaboration with £15.9m project on next-gen human disease modelling

The Medical Research Council, Wellcome Trust and Innovate UK will work with MDC to develop advanced, specific and highly reproducible human-based in vitro models of disease, with the aim of making them widely available to researchers in academia and industry
Research & Development

Patient dies in CRISPR gene therapy trial

The FDA has now placed Intellia Therapeutics' Phase III CRISPR trials on hold over raised liver enzymes
Subscribe now